Vaxcyte Company Insiders

Vaxcyte Management Team Effectiveness

The company has return on total asset (ROA) of (0.1494) % which means that it has lost $0.1494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2106) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Vaxcyte's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 1.2 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024. Common Stock Shares Outstanding is likely to drop to about 57.4 M in 2024. Net Loss is likely to rise to about (191.1 M) in 2024

Vaxcyte Workforce Comparison

Vaxcyte Insider Trading History

Vaxcyte Notable Stakeholders

The success or failure of an entity such as Vaxcyte often depends on how effective the management is. Vaxcyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaxcyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaxcyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Vaxcyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxcyte. Check Vaxcyte's Beneish M Score to see the likelihood of Vaxcyte's management manipulating its earnings.

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.